pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·22h ago·1 min read
save

Eli Lilly consolidates US and international sales under new global markets unit as veteran exec retires

Oct 29, 2026·read at Fierce Biotech ↗Neutral

Eli Lilly announced that long‑time executive Patrik Jonsson will retire after 36 years with the company. Jonsson has been serving as executive vice president and president of Lilly International, overseeing the drugmaker's non‑U.S. commercial operations.

Effective Jan. 1, 2027, Lilly will merge its U.S. and international commercial divisions into a single organization called Lilly Global Markets. The company named Ilya Yuffa, currently head of Lilly USA and former president of Lilly International, as the first president of the new unit.

CEO David Ricks said Yuffa’s experience running both domestic and overseas businesses positions him to lead Lilly’s customer‑facing operations worldwide. The restructuring aims to streamline the company’s global sales and marketing efforts.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires”

read at Fierce Biotech ↗
814 words · retrieved 23m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY21ELI LILLY CO5Lilly USA LLC3ENANTA PHARMACEUTICALS INC2LEADING2Celea TherapeuticsNOVOOVERSEASProtara Therapeutics, Inc.TARSUSUltragenyx Pharmaceutical Inc.
drugs
ImmunologyT-Cell TherapyTP-04TP-05lonafarniblotilaner
topics
Oncology3Gene Therapy (AAV)2Pulmonary Fibrosis2Pulmonology2Small Molecule2ApprovalCell TherapyColorectal CancerImmunologyInfectious DiseaseKRASOphthalmologyPainRare Disease

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech
  • 1d agoLENZ cuts 75% of staff as third quarter earnings disappointBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 23Fierce Biotech Layoff Tracker 2026: Enlivex excises 60%; Eyepoint halves headcountFierce Biotech
  • 2d ago5 new drug launches that defied industry expectationsBioSpace